Nov 6, 2013
Global Green, Inc. to Proceed with Plans to Construct a Manufacturing Facility
Tallahassee, Fla – Global Green, Inc. (OTCBB:GOGC), a green bio-pharmaceutical company, today announced that it has made a tactical decision to proceed with the design and development of plans to construct a manufacturing facility for the production of its Salmogenics Vaccine.
The facility would enable the company to ramp up its production with more ease, rather than to wait for manufacturing slots in the existing pharmaceutical industry, for its vaccine production. The facility would initially be about 40,000 square feet, with room for adjacent expansion, should future growth warrant it. The company believes that it could have the facility built and operational in about 18 months after funding is secured. This facility could also produce other vaccines, should the company develop or acquire those in the future. The company estimates that the facility at its initial stage would cost about $10,000,000, but would enable it to produce its vaccines for sale on a consistent and reliable basis.
Dr. Mehran Ghazvini, DC, NMD, Chairman and CEO, stated “The company does not yet have committed financing for the facility, but is exploring industrial enterprise zones and bond financing, as well as discussing the plans for funding with investment banking entities, both in the U.S. and Europe.”
About Global Green, Inc.
Global Green, Inc. is a green bio-pharmaceutical company committed to identifying technology platforms and commercializing vaccines that contain natural organisms that are not genetically modified, utilizing pharmaceutical standards without the use of mercury. For more information, visit www.globalgreeninc.com.
This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that such forward-looking statements involve risks and uncertainties which include, among others, the inherent uncertainties associated with smaller reporting companies including, without limitation, other risks detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission.